Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 11;13(11):e19487.
doi: 10.7759/cureus.19487. eCollection 2021 Nov.

Evaluating the Clinical Outcomes of Remdesivir Among Patients Admitted With COVID-19 in a Tertiary Care Hospital

Ahmad G Butt  1 , Jahanzeb Ahmed  2 , Syed Muhammad Huzaifa Shah  3 , Camilo Andrés Avendaño Capriles  4   5 , Hady Al-Rihani  6 , Bilal Ahmed  7 , Muhammad Salman  7 , Arti Devi  3 , Sher Wali  8
Affiliations

Evaluating the Clinical Outcomes of Remdesivir Among Patients Admitted With COVID-19 in a Tertiary Care Hospital

Ahmad G Butt et al. Cureus. .

Retraction in

Abstract

Introduction: This study was conducted to determine whether remdesivir administration for treatment of coronavirus disease 2019 (COVID-19) is associated with reducing deaths among COVID-19 hospitalized patients.

Methodology: It was a retrospective study, and the data was acquired at Ziauddin Hospital in Karachi, Pakistan. All patients admitted between February and May 2021 with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection confirmed by polymerase chain reaction testing from nasopharyngeal samples were included in the study, including those who received at least five-day treatment of remdesivir and who did not receive even a single dose of remdesivir.

Results: Data of overall 174 patients were used, out of which 71 (40.80%) received remdesivir. After propensity score matching, 71 patients in the remdesivir group were successfully matched with the non-remdesivir patients on the basis of age, gender, and disease severity. Results of multivariable logistic regression showed that there is no significant difference in deaths between patients who received remdesivir and patients who did not receive remdesivir (p-value=0.122). However, the length of hospital stay was significantly lower in the remdesivir group than in the control group (p-value=0.001).

Conclusion: Results of this study can provide evidence that remdesivir can be efficient in reducing the duration of COVID-19 illness, and a five-day course of treatment is sufficient for patients to get clinical benefits.

Keywords: clinical outcomes; covid-19; impact; remdesivir; sar-cov 2 infection; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Similar articles

See all similar articles

Cited by

References

    1. A need for open public data standards and sharing in light of COVID-19. Gardner L, Ratcliff J, Dong E, Katz A. Lancet Infect Dis. 2021;21:0. - PMC - PubMed
    1. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant . Bernal JL, Andrews N, Gower C, et al. N Engl J Med. 2021;385:585–594. - PMC - PubMed
    1. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Jorgensen SC, Kebriaei R, Dresser LD. Pharmacotherapy. 2020;40:659–671. - PMC - PubMed
    1. Aa randomized, controlled trial of Ebola virus disease therapeutics. Mulangu S, Dodd LE, Davey RT Jr, et al. N Engl J Med. 2019;381:2293–2303. - PMC - PubMed
    1. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Wang Y, Zhang D, Du G, et al. Lancet. 2020;395:1569–1578. - PMC - PubMed

Publication types

LinkOut - more resources